NATURAL HISTORY AND TREATMENT OF CHRONIC NON-A, NON-B HEPATITIS

有充分记录的慢性非甲非乙型肝炎患者有 正在进行评估，以确定这种共同的长期自然历史 慢性肝病的一种形式。一群这样的患者可以 评估这种疾病的实验性治疗方法。一个有远见的， 随机、安慰剂对照、双盲试验，疗程6个月 人类α-干扰素在慢性NANB肝炎患者中的应用 完成。41名患者已完成前6个月(盲法) 研究的阶段。21人接受干扰素治疗，20人接受安慰剂治疗。平均 血清转氨酶活性和肝组织学改善 在接受干扰素治疗的患者中显著，但在安慰剂接受者中不显著。 最初接受安慰剂治疗的18名患者被交叉至 接受干扰素治疗12个月。他们也对此做出了类似的反应 患者治疗6个月，尽管他们的长期应答率可能 再高一点。

Patients with well-documented chronic non-A, non-B (NANB) hepatitis are being evaluated to determine the long-term natural history of this common form of chronic liver disease. A cohort of such patients are available to evaluate experimental therapies for this disease. A prospective, randomized, placebo-controlled, double-blind trial of a six month course of human alpha interferon in patients with chronic NANB hepatitis has been completed. Forty-one patients have completed the first 6 month (blinded) phase of the study. Twenty one received interferon and 20 placebo. Mean serum aminotransferase activities and liver histology improved significantly in interferon-treated patients but not in placebo recipients. Eighteen patients who initially received placebo were crossed over to receive interferon for 12 months. They have had a similar response to the patients treated for 6 months, although their long-term response rate may be higher.